Shares Outstanding: 20.74M
% Held by Insiders: 59.17%
% Held by Institutions: 23.90%
Shares Short (as of Dec 31, 2015): 278.09K
Short Ratio (as of Dec 31, 2015): 2.04
Short % of Float (as of Dec 31, 2015): 3.72%
Shares Short (prior month): 212.57K
Company Profile - Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its development stage products include AGS-003, which is under Phase III clinical trials for the treatment of metastatic renal cell carcinoma and other cancers; and AGS-004, which is in phase 2 clinical trial for the treatment of Human Immunodeficiency Virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.